Sep. 4 at 5:58 PM
Guggenheim y'day assumed coverage of
$RLAY Buy-
$15-Best Idea.
Scorpion -
$LLY $NVS RHHBY
BPMC -
$SNY SWTX -
$MRK DCPH - OPHLY
Guggenheim said: If we woke up with no memory of the history of how biotech stocks got to trade as they do today, we think one of the first questions investors might ask is "Why is
$RLAY trading below cash?"
This investment thesis contains an ongoing, fully-funded ph.3 breast cancer trial for RLY-2608, an oral, selective, pan-mutant PI3Ka inhibitor with a clean safety profile.
Guggenheim added:
